Bluejay Diagnostics, Inc. (BJDX) News
Filter BJDX News Items
BJDX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BJDX News Highlights
- BJDX's 30 day story count now stands at 3.
- Over the past 1 day, the trend for BJDX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- DEC, ICU and PRE are the most mentioned tickers in articles about BJDX.
Latest BJDX News From Around the Web
Below are the latest news stories about BLUEJAY DIAGNOSTICS INC that investors may wish to consider to help them evaluate BJDX as an investment opportunity.
Bluejay Diagnostics Announces Pricing of $3.5 Million Public OfferingACTON, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the pricing of a public offering of 2,692,308 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,692,308 shares of common stock at a combined offering price of $1.30 p |
BJDX: SYMON Says: Start the Trial!By John Vandermosten, CFA NASDAQ:BJDX Bluejay Diagnostics, Inc. (NASDAQ:BJDX) issued a press release on December 27th, 2023 informing stakeholders that the clinical study evaluating the Symphony diagnostic in sepsis patients has started. The trial has been designated SYMON: Multicenter Sy mphony IL-6 Mon itoring Sepsis ICU Study. The study has been listed on the clinicaltrials.gov website under |
Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)This Study performs unique rapid on-site measurements of interleukin-6 (IL-6) and positions Company to move forward with multiple initiatives. ACTON, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), today announced the initiation of a multicenter clinical study to evaluate the Symphony IL-6 test in sepsis patients (the SYMON study). The Symphony System is designed to address the need for simple, reliable, rapid, near-patient testing |
Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial ResultsACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a clinical-stage medical diagnostics company developing rapid, near-patient tests using whole blood on its Symphony platform to improve patient outcomes in critical care settings, today reported its financial results for the quarter and nine months ended September 30, 2023. “Based on FDA’s feedback from the August 11, 2023, meeting, the Company focused on implementing the modifi |
BJDX: Toray License RenegotiationBy John Vandermosten, CFA NASDAQ:BJDX Bluejay Diagnostics, Inc. (NASDAQ:BJDX) has presented several pieces of material news in the last months adding a new CFO to its ranks, raising capital and renegotiating its license agreement with Toray Industries, Inc. Frances Scally was added as CFO of the company on September 26th following the former CFOs departure. The company raised gross proceeds of |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's time to start off the final trading day this week with a breakdown of the biggest pre-market stock movers on Friday! |
BJDX: FDA Meeting Confirms PathwayBy John Vandermosten, CFA NASDAQ:BJDX READ THE FULL BJDX RESEARCH REPORT 2Q:23 Financial and Operational Results Since our May initiation of Bluejay Diagnostics, Inc. (NASDAQ:BJDX), the company has regained compliance with the NASDAQ minimum bid price requirement following a reverse share split on July 24th. Bluejay is preparing to complete its pivotal trial and pursue a 510(k) FDA regulatory |
Bluejay Diagnostics Announces $1.59 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesACTON, Mass., Aug. 25, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that it has entered into a definitive agreement for the purchase and sale of 216,000 shares of the Company’s common stock at a purchase price of $7.365 per share of common stock in a registered direct offering priced at-the-mar |
Bluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial ResultsACTON, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, announced financial results for the six months ended June 30, 2023. “We continued to limit our cash burn during the quarter while executing our clinical strategy for the Symphony IL-6 test and are confident that our planned clinical and analyt |
Bluejay Diagnostics Regains Compliance with Nasdaq Minimum Bid Price RequirementACTON, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, announced today that on August 8, 2023, it received a notification letter (the "Notification Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it had regained compliance wi |